Novo Nordisk Pharma Ltd. (Representative Director and President: Keisuke Kotani, Headquarters: Chiyoda-ku, Tokyo; hereinafter "Novo Nordisk Pharma") announces the following personnel changes.

**① Executive Personnel (Effective March 1, 2026)**

| Name | New Position | Old Position | |---|---|---| | Ryo Kato (Kato Ryo) | Head of Medical Policy and External Affairs Division | Head of Public Affairs Department, Medical Policy and External Affairs Division |

| Name | New Position | Old Position | |---|---|---| | Junko McMaster (McMaster Junko) | Director of Corporate Affairs Department | ― |

**About Novo Nordisk**

Novo Nordisk is a leading global healthcare company headquartered in Denmark, founded in 1923. Our purpose is to drive change and defeat serious chronic diseases, building on our knowledge and experience gained in diabetes. To achieve this goal, we strive to discover scientific innovations, expand access to medicines, and ultimately prevent and cure diseases. Novo Nordisk currently employs approximately 68,800 people in 80 countries, and its products are sold in approximately 170 countries. Novo Nordisk Pharma Ltd., the Japanese subsidiary, was established in 1980.

FACT BOX

  • Source: PR TIMES
  • Category: 人事